The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics

Masal Ahmed, Isabelle Boileau, Bernard Le Foll, Andre F. Carvalho, Stefan Kloiber

Social anxiety disorder (SAD) is a highly prevalent psychiatric disorder that presents with an early age of onset, chronic disease course, and increased risk of psychiatric comorbidity. Current treatment options for SAD are associated with low response rates, suboptimal efficacy, and possible risk of adverse effects. Investigation of new neurobiological mechanisms may aid in the identification of more specific therapeutic targets for the treatment of this disorder. Emerging evidence suggests that the endogenous cannabinoid system, also referred to as the endocannabinoid system (ECS), could play a potential role in the pathophysiology of SAD. This review discusses the known pathophysiological mechanisms of SAD, the potential role of the ECS in this disorder, current drugs targeting the ECS, and the potential of these novel compounds to enhance the therapeutic armamentarium for SAD. Further investigational efforts, specifically in human populations, are warranted to improve our knowledge of the ECS in SAD.

Keywords: Social phobia; endocannabinoids; drug therapy; neurosciences; psychiatry

Introduction

Social anxiety disorder (SAD) is characterized by an excessive fear or anxiety of social situations wherein affected individuals worry they may behave in a manner that could lead to embarrassment, humiliation, or rejection by others. These fears may be restricted to performance-like situations, such as public speaking, but may also include more widespread social interactions, such as initiating a conversation or socializing at a gathering. As such, affected individuals typically avoid anxiety-provoking social stimuli. This enduring anxiety and avoidance often results in clinically significant psychosocial impairment, which interferes with the person’s daily routines, social engagements, relationships, occupation, and/or academic functioning.

SAD is a highly prevalent, predominantly youth-onset disorder which may affect 12.1% of individuals in the general population at least once in their lifetime. This disorder has a higher prevalence among females, often follows a chronic course, and has increased comorbidity with other psychiatric disorders. Common coexisting health conditions include major depressive disorder, generalized anxiety disorder, agoraphobia, substance use disorders, and increased rates of suicidal ideation, as well as physical health concerns such as cardiovascular disease. Individuals with SAD report higher unemployment rates, lower income, and greater financial dependency compared to those without SAD. Despite the significant socioeconomic costs and reduced quality of life associated with the disorder, only 35% of respondents with lifelong SAD reported seeking treatment specifically for social anxiety.

In terms of treatment, cognitive behavioral therapy (CBT) serves as a first-line psychotherapy approach for anxiety disorders. A 2018 meta-analysis reported a post-CBT effect size of $d = 1.37$, compared to effect sizes of $d = 1.33$ for other psychotherapies and $d = 0.88$ for psychological or pill placebo. Pharmacological treatment with selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) has also been demonstrated to yield clinical improvement in SAD patients. A 2019 meta-analysis examining 23 randomized-controlled SAD studies reported a standardized mean difference of 0.66 and 0.67 with respect to the measured treatment benefit of SSRIs and SNRIs compared to placebo. A moderate response has been described for treatment with benzodiazepines, although these drugs have been associated with multiple adverse effects, including physiological dependence, withdrawal

Correspondence: Stefan Kloiber, Centre for Addiction and Mental Health, 100 Stokes City, Toronto, ON, Canada, M6J 1H4. E-mail: stefan.kloiber@camh.ca
Submitted Mar 31 2021, accepted Jun 15 2021.

How to cite this article: Ahmed M, Boileau I, Le Foll B, Carvalho AF, Kloiber S. The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics. Braz J Psychiatry. 2021;00:000-000. http://dx.doi.org/10.1590/1516-4446-2021-1926
symptoms, and impaired cognition when used over longer periods of time. Anticonvulsants (pregabalin and gabapentin), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase A, and tricyclic antidepressants (TCAs) have also demonstrated efficacy in the treatment of SAD. MAOIs and TCAs carry a higher risk of severe adverse effects and interactions (for MAOIs, e.g., hypertension, serotonin syndrome, potentially dangerous interactions with other antidepressants or food requiring specific dietary restrictions; for TCAs, e.g., anticholinergic effects, cardiac adverse effects) compared to newer antidepressants such as SSRIs and SNRIs.

Overall, current therapeutic options demonstrate suboptimal response rates, limited efficacy, and include risk for potentially severe side effects with certain medications, such as benzodiazepines or MAOIs. The relative paucity of effective treatments for this disorder may be partly due to our limited understanding of the pathophysiology of SAD, despite research efforts implicating several biological systems. Investigation of new neurobiological mechanisms may facilitate the discovery of more specific therapeutic targets for SAD and could aid in the future identification of biomarkers. One notable target includes the endogenous cannabinoid system (ECS), which emerging evidence suggests may mediate aspects of anxiety and social behavior.

This article aims to provide a narrative summary of the pathophysiological mechanisms involved in SAD, give an overview of the potential pathophysiological role of the ECS in SAD, and discuss future research directions and potential therapeutic agents for SAD targeting the ECS.

Known pathophysiological mechanisms of SAD

Behavioral inhibition and neurocircuitry in SAD

Behavioral inhibition (BI), described as a childhood tendency to withdraw from unfamiliar situations, people, and environments, has been associated with the development of SAD across several prospective studies. A 2020 meta-analysis found that behaviorally inhibited children had significantly increased odds of developing SAD (odds ratio = 5.84), indicating that childhood BI may be a risk factor/predictor of the disorder. One hypothesis suggests that BI is associated with either a lower threshold for or a stronger response to the detection of novel, salient, or threatening information, thereby implicating disruptions in certain neural circuitry. This is supported by studies which found that individuals with a childhood history of BI exhibit a greater striatal response to reward and punishment cues, as well as heightened activity in regions including the prefrontal cortex (PFC) and anterior cingulate cortex (ACC). Greater amygdala reactivity to novel stimuli has also been reported in adolescents and adults who exhibited BI during childhood.

These findings fall in line with those of functional imaging studies in persons with SAD. Results from such studies consistently demonstrate abnormal activity in regions including the amygdala, insula, PFC, and ACC, dubbed the “corticolimbic circuit.” Notably, heightened amygdalar and insular activities have been observed in response to performing stressful social tasks or viewing negative facial expressions, which in some studies has also correlated positively with the severity of SAD symptoms. Although less consistent in direction, abnormal activity has also been reported in the PFC and ACC of subjects with SAD compared to controls.

Collectively, these findings suggest that the neurobiology of childhood BI may be associated with corticolimbic disruptions contributing to the development of SAD.

Neurotransmitter systems in SAD

The monoamine hypothesis and pharmacological approaches suggest that the neurobiologies of depression and anxiety share imbalances in the monoaminergic neurotransmission system. This in regard, neuro-molecular positron emission tomography (PET) and single photon emission computed tomography (SPECT) studies in SAD have largely focused on imaging serotonergic and dopaminergic neurotransmission, based on the reported efficacy of antidepressants.

Two PET studies examining presynaptic serotoninergic activity found elevated rates of serotonin synthesis in the hippocampus, basal ganglia, amygdala, and ACC of individuals with SAD. Additionally, three studies employing two different tracers ([C-11]DASB PET and [I-123]-[I-CIT SPECT]) reported higher serotonin receptor binding potential (a measure of receptor expression) within the raphe nuclei, caudate nucleus, insular cortex, nucleus accumbens, and thalamus. Only one study investigated postsynaptic serotonergic function in SAD, in which PET imaging of [carbonyl-C-11]WAY-100635 demonstrated significantly reduced serotonin 1A receptor binding potential in the amygdala, insula, and ACC of patients with SAD.

Imaging of dopaminergic systems has produced less consistent results. Three studies employing [I-123]-[I-CIT SPECT reported either an increase, decrease, or no difference in dopamine transporter binding in the striatum. As suggested by Schneier et al., these discrepancies could possibly be due to small sample sizes or differences in SPECT assessment methods (receptor blocking compound, identification of volumes of interest or reference regions). Another SPECT study reported significantly reduced dopamine D2/D3 receptor binding potential in the striatum of patients with SAD and comorbid obsessive-compulsive disorder compared to healthy controls. However, the same group found no difference in striatal dopamine D2/D3 receptor binding in a subsequent PET study, which employed a more reliable dopamine measurement technique and used a larger SAD sample size. The latter study also reported a decrease in striatal dopamine D2/D3 receptor binding following an amphetamine challenge. Some of the observed differences may be due to variations in age range, symptom severity, treatments, and disease duration of the study cohorts, as well as varying strengths and limitations of the different imaging techniques and tracers employed in the aforementioned studies. While some of these findings suggest that serotonergic and dopaminergic...
activity may play a role in SAD, the limited and inconsistent results warrant further investigation to better understand the role of these neurotransmitter systems in SAD pathophysiology.

**The hypothalamic-pituitary-adrenal axis in SAD**

It has been well established that the hypothalamic-pituitary-adrenal (HPA) axis plays a major role in stress regulation. Activation of the HPA axis leads to increased corticotropin-releasing-hormone (CRH) signaling in the limbic forebrain, which, in turn, stimulates the downstream release of cortisol. While acute stress leads to adaptive activation of the HPA axis with a transient increase in cortisol, chronic stress can result in prolonged activation of the HPA axis via dysregulation of glucocorticoid-mediated feedback inhibition. These disruptive processes may affect the coping mechanisms established by CRH systems, leading to chronic symptoms of fear and anxiety.

Previous studies have demonstrated that individuals with SAD have significantly elevated stressor-induced cortisol levels compared to controls. However, these findings are not consistent: other studies employing similar stress paradigms found no significant difference in cortisol levels. These discrepancies may be due to variable length of stressor exposure, perception of risk posed by the stressor, comorbidities, or age, which are known to influence cortisol response. Interestingly, emerging evidence suggests that the ECS may contribute to the regulation of HPA axis activity. As such, improved understanding of ECS processes may provide insight into the possible aberrations in the HPA axis stress response involved in the pathophysiology of SAD.

**The endocannabinoid system**

The ECS is a lipid-based signaling system of the central and peripheral nervous system (Figure 1). The ECS is primarily composed of two G protein-coupled cannabinoid receptors, endogenous cannabinoid ligands, and enzymes responsible for ligand synthesis and degradation. Cannabinoid type 1 (CB1) receptors are the predominant cannabinoid receptors in the central nervous system (CNS) and mainly located on terminals of central and peripheral neurons. Activation of these receptors inhibits neurotransmitter release, primarily from GABAergic and glutamatergic neurons as well as certain monoaminergic sites. In contrast, cannabinoid type 2 (CB2) receptors are primarily distributed in peripheral tissues and immune system cells, where they modulate cell migration and cytokine release.

The two main endocannabinoids, N-arachidonoylthanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG), are lipid ligands that are synthesized and released on demand from the post-synaptic cell, leading to a retrograde suppression of neurotransmitter release. Other lipid ligands of cannabinoid receptors include 2-arachidonoylglycerol ether, N-arachidonoyl dopamine, N-oleoyl dopamine, O-arachidonoylthanolamine, and oleamide. Signaling is terminated via metabolization of AEA and 2-AG through their catabolic enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively.

These endocannabinoids, collectively with their receptors, biosynthetic proteins, and degradative enzymes, are referred to as the ECS (Figure 1).

**Role of the endocannabinoid system in the regulation of stress and anxiety**

Over the last two decades, the ECS has emerged and been recognized as a potential regulator of stress and anxiety. Cannabis consumption studies investigating the exogenous cannabinoid delta-9-tetrahydrocannabinol (THC) found that, in addition to its addictive potential, THC consumption produces biphasic physiological effects depending on dose. Notably, low-dose THC consumption has been associated with anxiolytic effects, whereas high-dose consumption has been linked to anxiogenic effects. Given that the psychoactive effects of THC are mediated by CB1 receptor activation, it is possible that ECS signaling may serve to buffer against anxiety and stress symptoms.

Animal studies have converged to show that increasing ECS activity via pharmacological stimulation of CB1 receptors (via CB1 agonism or via elevating AEA/2-AG through inhibition of their degradative enzymes) decreases behavioral measures of rodent anxiety. Conversely, decreasing ECS activity via antagonism or deletion of the CB1 receptor gene elicits an anxiogenic response. These anxiolytic effects seem to depend on CB1 activation in key structures implicated in the fear response, particularly those comprising the corticolimbic circuit. In this regard, studies have shown that increased amygdala neuron excitability in rodents exposed to stress can be corrected by FAAH inhibition. Moreover, rodent models of anxiety, modeled via exposure to stress paradigms, consistently demonstrate elevated FAAH activity and reduced AEA levels in limbic areas, further supporting the anxiolytic potential of the ECS via FAAH inhibition. While the status of 2-AG and MAGL in anxiety is less studied, pharmacological and genetic investigations suggest that enhanced 2-AG signaling may play an important role in reducing anxiety-like behaviors and promoting adaptation under conditions of repeated stress exposure (reviewed by Bedse et al.). Several studies have also shown that systemic MAGL inhibition reduces anxiety-like behaviors under basal and highly aversive conditions, as well as chronic stress-induced anxiety-like behaviors.

In line with the preclinical literature, human research has shown that treatment with the CB1 inverse agonist/receptor blocker rimonabant increases symptoms of anxiety and depression in some individuals. Due to serious psychiatric adverse effects, including suicidal ideation, rimonabant was withdrawn worldwide, in an example of the potency and potential risks associated with manipulation of the ECS. Moreover, biochemical studies in humans have found that experimental exposure to the Trier Social Stress Test (TSST) increases serum
concentrations of AEA, 2-AG and the other N-acylethanolamines immediately after the stress period, both in healthy participants (compared to unstressed controls) and in those diagnosed with major depression (compared to TSST-exposed controls). In the former study, baseline anxiety ratings also correlated negatively with baseline AEA concentrations. Similarly, among individuals with PTSD, those with lower peripheral AEA levels experienced more intrusive symptoms. Clinical studies examining the FAAH C385A genetic polymorphism (rs324420) found that carriers of the A allele – which is associated with lower FAAH and higher AEA levels – have a blunted amygdalar response to threat, greater ventral striatum response to reward, decreased correlation of amygdala reactivity and trait anxiety, enhanced fronto-amygdalar connectivity, and reduced stress reactivity. Green et al. failed to replicate the aforementioned relationship between the FAAH C385A polymorphism and amygdalar functional connectivity, possibly due to a small sample size. However, they did find that FAAH levels measured in vivo in the human brain are negatively correlated with fronto-amygdalar functional connectivity, suggesting that higher brain levels of AEA could increase coupling strength in fronto-amygdalar networks and affect stress response. Another recent fMRI study in healthy males showed that neural activation of the anterior cingulate cortex and anterior insular cortex during extinction learning correlated positively with AEA baseline levels. Moreover, task-related changes in AEA were observed during fear extinction, suggesting that AEA may play a putative role in fear extinction learning. Finally, in the remarkable case report of a patient presenting with pain insensitivity and low fear and anxiety, the C385A polymorphism together with a microdeletion linked to decreased FAAH expression was detected as a possible causal factor. In addition, blood levels of AEA and other fatty-acid amides which are degraded by FAAH were unusually elevated in this individual.

The role of the ECS specifically in social anxiety is supported by various preclinical findings which demonstrate effects of ECS modulation, via either CB1 receptor activation or FAAH inhibition, on social interaction and social anxiety. In comparison, clinical studies investigating this system in SAD are considerably limited. A recent clinical trial investigating the therapeutic effects of a FAAH inhibitor in SAD was negative. However, the authors observed a small to modest anxiolytic effect in patients with severe SAD and suggested that, based on the correlation between low trough concentrations of the inhibitor (i.e., the lowest concentration of the drug in the bloodstream) and low plasma AEA, future trials with a higher dose of the inhibitor may be warranted. In addition, a recently published double-blind, placebo-controlled experimental study in healthy adults found that administration of the FAAH inhibitor PF-04457845 produced a 10-fold increase in peripheral AEA levels and

Figure 1 Illustration of endocannabinoid biosynthesis, binding, and metabolism. A) The biosynthesis of 2-AG is mediated by sequential hydrolysis, whereby a GPL is hydrolyzed by PLC or PLD to form DAG. DAG is then rapidly hydrolyzed by DAGL to form 2-AG. B) 2-AG is primarily broken down by MAGL to form arachidonic acid and glycerol. C) AEA is synthesized from phospholipid precursors PPEA which are initially converted to NAPE by NAT. NAPE is subsequently converted to AEA by NAPE-PLD activity. D) AEA is primarily metabolized by FAAH to form arachidonic acid and ethanolamine. E) Both 2-AG and AEA bind to CB1 on the presynaptic neuron. F) After receptor activation, AEA and 2-AG are transported back into the neuron by EMT. 2-AG may be converted to AEA through alternative pathways. 2-AG = 2-arachidonoylglycerol; AEA = anandamide; CB1 = cannabinoid receptor 1; DAG = diacylglycerol; DAGL = DAG lipase; EMT = endocannabinoid membrane transporters; FAAH = fatty acid amide hydrolase; GPL = glycerophospholipid; MAGL = monoacylglycerol lipase; NAPE = N-arachidonoylphosphatidylethanolamine; NAPE-PLD = NAPE phospholipase D; NAT = N-acyltransferase; PLC = phospholipase C; PLD = phospholipase D; PPEA = phosphatidylethanolamine.
decreased broad-spectrum fear-related phenotypes. Furthermore, a 2021 double-blind, placebo-controlled clinical trial in healthy males employing the FAAH inhibitor JNJ-42165279 found that the drug attenuated activation in the amygdala, anterior cingulate, and bilateral insula during a face emotion processing task – effects which are consistent with those of previously observed anxiolytic agents. Moreover, higher levels of plasma AEA were associated with greater attenuation in these brain regions. While the latter two clinical studies were not conducted in a population with SAD, they suggest that FAAH inhibitors may have some potential in the treatment of fear-related disorders such as SAD.

Over the past two decades, cannabidiol (CBD), the primary non-psychotomimetic cannabinoid constituent of cannabis, has emerged as a drug with multiple potential therapeutic benefits including neuroprotective, anti-inflammatory, antioxidative, antipsychotic, and anti-anxiety effects (reviewed by McPartland et al. Although evidence is emerging that the anxiolytic effects of CBD may be mediated through serotoninergic 5HT1a receptors and vanilloid receptor type 1 (TRPV1) receptors, some of these effects may also be exerted through modulation of the ECS. Specifically, mild agonistic effects on CB1 receptors and antagonistic effects on exogenous CB1 receptor agonists (THC) have been described. While the agonistic effects are still limited and controversial, emerging evidence suggests that CBD may act as a negative allosteric modulator of CB1 receptors, resulting in the aforementioned antagonistic effects on cannabinoid agonist activity. Furthermore, there have been inconsistent findings on the effects of CBD on FAAH activity. Some animal studies found an inhibitory effect of CBD on FAAH activity in brain tissue of healthy mice, whereas in vivo treatment of mouse glioma tissue with CBD increased FAAH activity. In addition, two studies reported a decrease in FAAH protein expression following CBD administration in chronically stressed mice and LPS-treated mice. Further investigation with more standardized methodologies may help elucidate the actions of CBD on FAAH.

Moreover, several preclinical studies investigating effects of CBD in different animal models of anxiety have repeatedly demonstrated anxiolytic effects, as comprehensively reviewed by Blessing and colleagues. Among these, some animal studies have found that CBD produces anxiolytic effects following an inverted U-shaped dose-response curve. Interestingly, this bell-shaped response is not exclusive to the anxiolytic effects of CBD, as it has also been observed in animal models of depression, compulsive behavior, schizophrenia, cognitive impairment, and other ailments. These findings suggest that the optimal dose of CBD may depend on condition, indicating the need to test different doses in animals and humans in order to elucidate its therapeutic potential for the treatment of SAD and other anxiety disorders.

In terms of clinical findings, one study in human cells suggests that CBD increases AEA levels through binding to fatty acid-binding proteins and thereby prevents AEA uptake and catabolism by FAAH, rather than inhibiting FAAH directly. In addition, results from a clinical trial in schizophrenia indicate higher AEA levels in individuals receiving treatment with CBD. While direct measurement of brain FAAH activity has been made possible by the novel PET radiotracer [C-11]CURB, there have been to our knowledge no studies directly investigating brain FAAH activity before and after treatment with CBD. Finally, three randomized-controlled clinical trials in SAD have shown that CBD may improve SAD symptoms (Table 1). Although these results appear to be promising, it should be noted that these trials were conducted in small samples (10 to 37 participants) and employed inconsistent assessment tools across studies. Such limitations warrant further investigation to produce robust findings and better understand the biological mechanisms of CBD action in SAD.

Interaction of the endocannabinoid system with other systems and biological findings

As discussed, previous research has largely focused on establishing monoaminergic impairment affecting the limbic system and dysfunction of the HPA axis as pathophysiologically mechanisms of SAD. Accordingly, treatments developed and/or tested for SAD have mainly targeted serotonin (5-HT) and norepinephrine (NE) neurotransmission, specifically via drugs blocking their reuptake. However, these drugs are ineffective in more than one-third of SAD patients. Recently, the ECS has been identified as a modulator of the aforementioned systems and incited interest in the development of new pharmacological treatments for mood and anxiety disorders. In particular, two preclinical studies found that synthetic CB1 receptor agonism was associated with increased NE efflux and anxiety-like behavior in healthy rodents. The latter study also showed that local administration of a CB1 receptor antagonist (SR 141716A) followed by local administration of a CB1 receptor agonist (WIN55,212-2) produces a paradoxical inhibition of NE efflux. Together, these findings suggest that enhanced NE activity may be mediated, in part, by direct CB1 receptor agonism, localized at noradrenergic axon terminals. However, the paradoxical decrease in NE observed in the second study may also indicate that NE efflux is modulated indirectly via interneurons or other chemically distinct afferents. Similarly, direct or indirect stimulation of CB1 receptors has been linked to enhanced 5-HT neuronal activity. However, these studies found that increased 5-HT neurotransmission following CB1 receptor agonism, FAAH inhibition, or FAAH knockout was associated with enhanced stress-coping behaviors and antidepressant effects in otherwise healthy rodents.

Accumulating evidence also suggests that the ECS may act as a homeostatic regulator of HPA axis activity under basal and stress-related conditions. In this regard, studies have found that chronic stress exposure or repeated corticosterone treatment activate the HPA axis response, which has been associated with changes...
in AEA levels, FAAH activity, and CB1 receptor expression.\textsuperscript{90,159-161} Moreover, Di et al.\textsuperscript{162} showed that the paraventricular nucleus (PVN) participates in glucocorticoid-mediated feedback regulation of the HPA axis via endocannabinoid release. Specifically, this model suggests that, during the stress response, activation of hippocampal glucocorticoid receptors (via corticosterone) induces the synthesis of endocannabinoid ligands which bind to CB1 receptors on glutamatergic neurons.\textsuperscript{162} This binding activates a signaling cascade that leads to the inhibition of glutamate release onto the hypothalamic PVN, decreasing PVN neuronal activity and further hormone secretion.\textsuperscript{162} It is possible, then, that disruption of certain ECS processes may lead to dysregulation of HPA axis activity, which together may contribute to the development of sustained anxiety-related symptoms.

ECS interactions with oxytocin, the neuropeptide that reinforces social bonding and social reward, have also been observed. Specifically, Wei et al.\textsuperscript{163} showed that oxytocin drives AEA mobilization in the mouse nucleus accumbens, leading to reinforcement of social reward behavior. Pharmacological blockade of oxytocin receptors attenuated this response, whereas FAAH inhibition or gene deletion offset the behavioral effects of oxytocin receptor blockade.\textsuperscript{163} These findings suggest that the ECS may modulate the prosocial effects of oxytocin, which may open potential avenues of research in disorders of social impairment such as SAD.

Genetic studies examining ECS candidate genes relating to anxiety disorders have produced limited findings. Current evidence suggests that a single nucleotide polymorphism in the *FAAH* gene (rs324420; C385A)\textsuperscript{164} influences FAAH protein expression,\textsuperscript{105,106} which has been found to correlate with trait anxiety.\textsuperscript{107} However, there is little to no evidence to support an association between genetic variants of other ECS genes and symptoms of SAD.

Thus, further investigation of ECS interactions with other biological systems and genetic variables may help improve our current knowledge and address the gap with respect to SAD pathophysiology, potentially allowing for the development of more targeted treatment options.

### Summary of current drugs targeting the endocannabinoid system

Based on current evidence, it appears that the ECS may play a role in buffering against stress and anxiety. Thus, targeting components of this system could serve as a potentially valid strategy for the treatment of social anxiety symptoms. In this regard, several ECS-targeting drugs have been developed, with some demonstrating promising therapeutic potential.

Logically, CB1 agonists were considered promising, given their ability to enhance ECS activity and reduce anxiety-like behaviors in rodents.\textsuperscript{80,164-166} Notable synthetic CB1 agonists include WIN55,212-2, CP-55940, and HU-210. Although these compounds are generally well-tolerated, accompanying risk of other psychotropic adverse effects has been observed.\textsuperscript{107} Direct CB1 agonism has also been associated with disturbances in social behavior and social play in some preclinical studies, prompting the exploration of other ECS targets.\textsuperscript{113,168-170}

One of the most effective strategies to target anxiety through modulation of the ECS has been inhibition of...
the endocannabinoid degradation enzymes FAAH and MAGL. This allows for the indirect activation of CB1 receptors by increased levels of AEA and 2-AG. Accumulating evidence has demonstrated the anxiolytic effects of FAAH inhibitors (URB597, PF-3845, and PF-04457845), most prominently in rodents, as well as the aforementioned human experimental PF-04457845 trial. Interestingly, prosocial effects of these compounds have also been consistently observed in rodent models of social impairment. Although more limited in study, MAGL inhibitors (URB602, JZL184) have demonstrated similar results in terms of improved anxiety and social behavior. While a handful of inhibitor studies have reported insignificant results, the vast majority suggest that inhibition of endocannabinoid degradation enzymes may serve as a promising novel treatment strategy for anxiety-related disorders.

The opposing effects on anxiety and social behavior exerted through direct versus indirect CB1R activation may be due to differences in the mechanism of action (e.g. partial vs full agonistic properties at CB1R) and/or affinities of endogenous vs synthetic ligands for CB1R vs CB2R affinity. However, this variability may also be explained by existing differences in the underlying status of the ECS in animals with social impairments, such as ECS receptor expression, ligand levels, or enzyme activity. These aspects warrant further investigation of changes in ECS components in social impairment models as well as in humans of studies of disorders associated with social impairment in order to validate the therapeutic potential and potential risks of these ECS-targeting agents in clinical settings.

In contrast, CB1 inverse agonists/antagonists have been shown to further exacerbate anxiety-like behaviors. As mentioned above the inverse agonist Rimonabant, found to be effective for weight-loss and smoking cessation, was quickly withdrawn following the emergence of severe psychiatric side effects. In line with this, CB1 inverse agonist, AM251 has been found to reduce social interactions in rodents and non-human primates. Interestingly and in contrast to CB1 inverse agonists, two preclinical studies found that administration of a CB1 neutral antagonist, AM4113, did not produce anxiogenic or depressive side effects when administered in rats. Similarly, two other rodent studies found that Rimonabant, but not the CB1 neutral antagonist tetrahydrocannabivarin, produced depressive and anxiogenic-like behaviors following administration. While inverse agonists induce a pharmacological response opposite to that of agonists, neutral antagonists do not activate the receptor – differences which may partly explain the absence of these behavioral side effects following administration of the latter group of agents.

Overall, the development of ECS-targeting agents has produced some promising results with regards to modulation of anxiety-like symptoms and social behavior, particularly in the field of FAAH and MAGL inhibitors. However, current evidence largely focuses on measures of general anxiety in animal models, and lacks the support of clinical trials. Further investigation of the effect of ECS-targeting drugs, specifically in animal models of social impairment and human studies, may provide greater insight as to how these compounds effect other biological systems, the possibility of risks and adverse effects, as well as their therapeutic potential in SAD.

**Future research and potential challenges**

This article highlights some of the currently known pathophysiological mechanisms of SAD and the therapeutic potential of the ECS. Targeting specific components of the ECS which have been shown to play a role in anxiety-related symptoms and social behavior may serve as a novel and possibly more targeted treatment for such disorders. However, there are a number of challenges to consider with respect to this new approach.

Firstly, while CB1 activation has been hypothesized to improve social anxiety-like behaviors by enhancing ECS signaling, activation of this receptor has since demonstrated increased risk of social impairments. While a handful of inhibitor studies have also demonstrated the ability to avoid certain CB1-related side effects. Despite these alternative solutions, the vast majority of currently supporting evidence is a result of animal experimentation. As such, the efficacy, safety, and tolerability of such drugs must be further validated through clinical studies to evaluate not only their therapeutic potential, but also their possible risks.

Secondly, it is important to consider that the ECS is a complex biological system that does not function in isolation, but rather through interactions with an array of other systems. In this regard, the ECS may interact with and modulate other systems including the endovanilloid, opioid, noradrenergic, prostaglandins, serotonergic, dopaminergic, glutamatergic, GABAergic systems, among other biological networks. Accounting for these additional biological networks will be crucial in understanding the larger physiological context and environment in which the ECS functions, and, by extension, the biological pathways that pharmacological interventions in the ECS can potentially influence.

A third challenge to consider is the pathophysiological heterogeneity of individuals with SAD. While the pathophysiological mechanisms of SAD are not yet certain, a number of biological systems have been described above which may additionally interact with the ECS. In this regard, it is possible that SAD in some individuals may be due to greater dysregulation of the HPA axis, whereas others may have more severe disruptions in their serotonergic/dopaminergic systems or inflammatory processes. Accordingly, it is possible that ECS-targeted treatment may be beneficial to certain
neurobiological subgroups of SAD patients, but potentially ineffective or even possibly harmful to others. As such, future research efforts should also focus on elucidating biological subpopulations in SAD and how ECS-targeted therapies could be individualized to maximize their therapeutic potential.

Conclusion

Overall, the ECS presents as a potential biological pathway in the pathophysiology of SAD and as promising avenue for developing novel therapeutic approaches. The lack of human ECS studies and clinical trials, combined with the complex nature of the ECS and the heterogenous pathophysiology of SAD, highlight significant gaps in our knowledge and possible challenges, though at the same time great potential for future research. Further investigational efforts – specifically in human populations – are warranted to improve our knowledge of the ECS in SAD and help clarify these emerging questions. In turn, such research may allow for the development of more targeted pharmacological treatment interventions for individuals with SAD.

Acknowledgements

SK is supported by the Academic Scholar Award and the Labatt Family Innovation Fund in Brain Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

Disclosure

BLF has obtained funding from Pfizer (GRAND Awards, including salary support) for investigator-initiated projects; has received some in-kind donation of cannabis product from Aurora and medication donation from Pfizer and Bioprojet, and was provided a coil for a TMS study from Brainsway; has obtained industry funding from Canopy (through research grants handled by Centre for Addiction and Mental Health [CAMH] or University of Toronto), Bioprojet, ACS, and Alkermes; has received in-kind donations of nabilomols from GW Pharma for past studies funded by CIHR and NIH; has served as a consultant for Shionogi; and is supported by CAMH and a clinician-scientist award from the Department of Family and Community Medicine of the University of Toronto and an Addiction Psychiatry Chair from the Department of Psychiatry of the University of Toronto. SK has received honoraria for past consultation for EmpowerPharm. The other authors report no conflict of interest.

References

1 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington: American Psychiatric Publishing; 2013.
2 Leichsenring F, Leweke F. Social anxiety disorder. N Engl J Med. 2017;376:2255-64.
3 Schneier FR, Johnson J, Horning CD, Liebowitz MR, Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992;49:282-8.
4 Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
5 Koyuncu A, Ince E, Ertekin E, Tükel R. Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges. Drugs Context. 2019;8:212573.
6 Ruscio AM, Brown TA, Chiw WT, Sareen J, Stein MB, Kessler RC. Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med. 2008;38:15-28.
7 Bandelow B, Sagebiel A, Belz M, Görlich Y, Michaels S, Wedekind D. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry. 2018;212:333-8.
8 Williams T, Hattingh CJ, Kariuki CM, Tromp SA, van Balkom AJ, Ipsen JC, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Syst Rev. 2017;10:CD001206.
9 Jakubovski E, Johnson JA, Nasir M, Müller-Vahl K, Bloch MH. Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders. Depress Anxiety. 2019;36:198-212.
10 Bystritsky A, Khalsa SS, Cameron ME, Schiffman J. Current diagnosis and treatment of anxiety disorders. P T. 2013;38:30-57.
11 Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016;41:80-102.
12 Wei D, Alisop S, Tye K, Piomelli D. Endocannabinoid signaling in the control of social behavior. Trends Neurosci. 2017;40:385-96.
13 Kagan J, Reznick JS, Clarke C, Snidman N, Garcia-Coll C. Behavioral inhibition to the unfamiliar. Child Dev. 1984;55:2212-25.
14 Schwartz CE, Snidman N, Kagan J. Adolescent social anxiety as an outcome of inhibited temperament in childhood. J Am Acad Child Adolesc Psychiatry. 1999;38:1008-15.
15 Prior M, Smart D, Sanson A, Oberklaid F. Does shy-inhibited temperament in childhood lead to anxiety problems in adolescence? J Am Acad Child Adolesc Psychiatry. 2000;39:461-8.
16 Biederman J, Hirshfeld-Becker DR, Rosenberg BA, Hérot C, Friedman D, Snidman N, et al. Further evidence of association between behavioral inhibition and social anxiety in children. Am J Psychiatry. 2001;158:1673-9.
17 Hirshfeld-Becker DR, Biederman J, Henin A, Faraoe SV, Davis S, Harrington K, et al. Behavioral inhibition in preschool children at risk is a specific predictor of middle childhood social anxiety: a five-year follow-up. J Dev Behav Pediatr. 2007;28:225-33.
18 Sandstrom A, Uher R, Pavlova B. Prospective association between childhood behavioral inhibition and anxiety: a meta-analysis. J Abnorm Child Psychol. 2020;48:57-66.
19 Clauss JA, Blackford JU. Behavioral inhibition and risk for developing social anxiety disorder: a meta-analytic study. J Am Acad Child Adolesc Psychiatry. 2012;51:1066-75.e1.
20 Fox NA, Buzzell GA, Morales S, Valadez EA, Wilson M, Henderson HA. Understanding the emergence of social anxiety in children with behavioral inhibition. Biol Psychiatry. 2021;89:881-9.
21 Bar-Haim Y, Fox NA, Benson B, Guyer AE, Williams A, Nelson EE, et al. Neural correlates of reward processing in adolescents with a history of inhibited temperament. Psychol Sci. 2009;20:1009-18.
22 Guyer AE, Nelson EE, Perez-Edgar K, Hardin MG, Roberson-Nay R, Monk CS, et al. Striatal functional alteration in adolescents characterized by early childhood behavioral inhibition. J Neurosci. 2008;28:6399-405.
23 Guyer AE, Benson B, Choaite VR, Bar-Haim Y, Perez-Edgar K, Jarcho JM, et al. Lasting associations between early-childhood temperament and late-adolescent reward-circuitry response to peer feedback. Dev Psychopathol. 2014;26:229-43.
24 Hellstein SM, Benson B, Perez-Edgar K, Bar-Haim Y, Detloff A, Pine DS, et al. Striatal responses to negative monetary outcomes differ between temperamentally inhibited and non-inhibited adolescents. Neuropsychologia. 2011;49:479-85.
25 Jarcho JM, Fox NA, Pine DS, Etkin A, Leibenluft E, Shechner T, et al. The neural correlates of emotion-based cognitive control in adults with early childhood behavioral inhibition. Biol Psychiatry. 2008;62:306-14.
26 Lam C, Walker OL, Degnan KA, Henderson HA, Pine DS, McDermott JM, et al. Cognitive control moderates early childhood
temperament in predicting social behavior in 7-year-old children: an ERP study. Dev Sci. 2014;17:667-81.

27 Pérez-Edgar K, Roberson-Nay R, Hardin MG, Poeth K, Guyer AE, Nelson EE, et al. Attention alters neural responses to evocative faces in behaviorally inhibited adolescents. Neuroimage. 2007;35: 1538-46.

28 Schwartz CE, Wright CJ, Shin LM, Kagan J, Rauch SL. Inhibited and uninhibited infants "grown up": adult amygdalar response to novelty. Science. 2003;300:1952-3.

29 Schwartz CE, Kunwar PS, Greve DN, Kagan J, Snidman NC, Bloch RB. A phenotype of early infancy predicts reactivity of the amygdala in male adults. Mol Psychiatry. 2012;17:1042-50.

30 Kovner R, Olier JA, Kalin NH. Cortico-limbic interactions mediate adaptive and maladaptive responses relevant to psychopathology. Am J Psychiatry. 2019;176:878-97.

31 Tillfors M, Furmark T, Marteinsdottir I, Fredrikson M. Cerebral blood flow during anticipation of public speaking in social phobia: a PET study. Biol Psychiatry. 2002;52:1113-9.

32 Lorberbaum JP, Kose S, Johnson MR, Arana GW, Sullivan LK, Tillfors M, Furmark T, Marteinsdottir I, Fredrikson M. Cerebral blood flow during anticipation of peer evaluation in patients with generalized social phobia. Neuroreport. 2004;15:2701-5.

33 Guyer AE, Lau JY, McClure-Tone EB, Parrish J, Shifrin ND, Reynolds RC, et al. Amygdala and ventrolateral prefrontal cortex function during anticipated peer evaluation in pediatric social anxiety. Arch Gen Psychiatry. 2008;65:1303-12.

34 Blair K, Geraci M, Devito J, McCaffrey D, Chen G, Vythilingam M, et al. Neural response to self-and other referential praise and criticism in generalized social phobia. Arch Gen Psychiatry. 2008;65:1176-84.

35 Stein MB, Goldin PR, Sareen J, Zorrilla LT, Brown GG. Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry. 2002;59:1027-34.

36 Yoon KL, Fitzgerald DA, Angstadt M, McCarron RA, Phan KL. Amygdala reactivity to emotional faces at high and low intensity in generalized social phobia: a 4-tesla functional MRI study. Psychiatry Res. 2007;154:93-8.

37 Phan KL, Fitzgerald DA, Nathan PJ, Tancer ME. Association between amygdala hyperreactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol Psychiatry. 2006;59:424-9.

38 Evans KC, Wright CJ, Wedig MM, Gold AL, Pollack MH, Rauch SL. A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder. Depress Anxiety. 2008;25:496-505.

39 Shah SG, Klumpp H, Angstadt M, Nathan PJ, Phan KL. Amygdala and insula response to emotional images in patients with generalized social anxiety disorder. J Psychiatry Neurosci. 2009;34:296-302.

40 Amir N, Klumpp H, Elias J, Bedwell JS, Yanasak N, Miller LS. Increased activation of the anterior cingulate cortex during processing of disgust faces in individuals with social phobia. Biol Psychiatry. 2006;59:1794-800.

41 Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509-22.

42 Donuyter AG, Dupont P, Stein DJ, Lochner C, Warwick JM. Nuclear neuroimaging in social anxiety disorder: a review. J Nucl Med. 2018;59:1794-800.

43 Furmark T, Marteinsdottir I, Frick A, Heurling K, Tillfors M, Appel L, et al. Serotonin synthesis rate and the tryptophan hydroxylase-2: a peripheral receptor for cannabinoids. Nature. 2008;103:561-4.

44 Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadasak W, Klunzinger M, Mien LK, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry. 2007;61:1081-9.

45 Tihonen J, Kuikka J, Bergstrom K, Lepola U, Koponen H, Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry. 1997;154:239-42.

46 Schneier FR, Abi-Dargham A, Martinez D, Stifstein M, Wang DR, Liebowitz MR, et al. Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder. Depress Anxiety. 2009;26:411-8.

47 Schneier FR, Liebowitz MR, Abi-Dargham A, Zee-Ponce Y, Lin SH, Laruelle M. Low dopamine D2 receptor binding potential in social phobia. Am J Psychiatry. 2000;157:457-9.

48 Faravelli C, Sauroc CL, Lelli L, Pietrini P, Lazzeretti L, Godini L, et al. The role of life events and HPA axis in anxiety disorders: a review. Curr Pharm Des. 2012;18:5663-74.

49 Hill MN, Tasker JG. Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience. 2012;204:5-16.

50 Schneier FR, Liebowitz MR, et al. Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder. Biol Psychiatry. 2007;61:1081-9.

51 Faravelli C, Sauroc CL, Lelli L, Pietrini P, Lazzeretti L, Godini L, et al. The role of life events and HPA axis in anxiety disorders: a review. Curr Pharm Des. 2012;18:5663-74.

52 van West D, Claes S, Solnon J, Deboutte D. Hypothalamic-pituitary-adrenal reactivity in prepubertal children with social phobia. J Affect Disord. 2008;111:281-90.

53 Yoon KL, Joormann J. Stress reactivity in social anxiety disorder with and without comorbid depression. J Abnorm Psychol. 2012;121: 250-5.

54 Martel FL, Hayward C, Lyons DM, Sanborn K, Varady S, Schatzberg AF. Salivary cortisol levels in socially phobic adolescent girls. Depress Anxiety. 1999;10:25-7.

55 Faravelli C, Sauroc CL, Lelli L, Pietrini P, Lazzeretti L, Godini L, et al. The role of life events and HPA axis in anxiety disorders: a review. Curr Pharm Des. 2012;18:5663-74.
Braz J Psychiatry. 2021;00(00)

10

M Ahmed et al.

71 Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuro-modulatory fatty-acid amides. Nature. 1996;384:83-7.

72 Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002;99:10189-24.

73 Connor JP, Stjepanovic D, Le Fol B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7:16.

74 Crippa JA, Zuardi AW, Martins-Santos R, Bhattacharyya S, Atakan Z, McGuire P, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24:515-23.

75 D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychopharmacological effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558-72.

76 Hunault CC, Böckner KB, Stellato RK, Kenemans JL, de Vries I, Meulenberg J. Acute subjective effects after smoking joints containing up to 69 mg delta-9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. Psychopharmacology (Berl). 2014;231:4723-33.

77 Rubino T, Sala V, Viganò D, Braida D, Castiglioni C, Lomvita V, et al. Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral δ 9-tetrahydrocannabinol in rats. Neuropsychopharmacology. 2007;32:2036-45.

78 Rubino T, Roitman N, Valenti M, Massi P, et al. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropsychopharmacology. 2008;34:151-60.

79 Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Effects of intra-amygdala infusion of cannabidiol on chronic stress-induced anxiety and amygdalar microstructure. Mol Psychiatry. 2013;18:1125-35.

80 Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F. Endocannabinoids in the brain. Mol Pharmacol. 1988;34:605-13.

81 Lin HC, Mao SC, Gean PW. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605-13.

82 Campolongo P, Roozendaal B, Trezza V, Hauer D, Schelling G, Lin HC, Mao SC, Gean PW. Effects of intra-amygdala infusion of cannabidiol on chronic stress-induced anxiety and amygdalar microstructure. Mol Psychiatry. 2013;18:1125-35.

83 Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, et al. Cannabidiol in animal models of stress and anxiety: preclinical evidence. Psychopharmacology (Berl). 2014;231:4723-33.

84 Tan H, Lauzon NM, Bishop SF, Bechard MA, Laviolette SR. Circulating endocannabinoids and mood disorders: priming a target for new therapies. Pharmacol Ther. 2013;138:16-37.

85 Lin HC, Mao SC, Gean PW. Effects of intra-amygdala infusion of cannabidiol on chronic stress-induced anxiety. Mol Psychiatry. 2013;18:1125-35.

86 Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, et al. 2-arachidonoylglycerol modulation of aversive memories. Nature. 2002;418:530-4.

87 Hariri AR, Gorka A, Hyde LW, Kimak M, Halder I, Ducci F, et al. Divergent effects of genetic variation in endocannabinoid signaling on human threat-and reward-related brain function. Biol Psychiatry. 2009;66:9-16.

88 Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Cannabidiol modulation of endocannabinoid activity in the rat basolateral amygdala enhances memory consolidation and enables glucocorticoid modulation of fear memory formation via functional inputs to the prelimbic cortex. J Neurosci. 2011;31:5300-12.

89 Bedse G, Hill MN, Patel S. 2-arachidonoylglycerol modulation of anxiety and stress adaptation: from grass roots to novel therapeutics. Biol Psychiatry. 2020;88:520-30.

90 Bedse G, Hartley ND, Neale E, Gaulden AD, Patrick TA, Kingsley PJ, et al. Functional redundancy between cannabinoid endocannabinoid signaling systems in the modulation of anxiety. Biol Psychiatry. 2017;82:488-99.

91 Patel S, Roelke CT, Rademaker DJ, Hillard CJ. Inhibition of restraint stress-induced neural and behavioural activation by endocannabinoid cannabidiolic signaling. Eur J Neurosci. 2005;21:1057-69.
Endocannabinoid system in SAD

111 Spohn J, Ulrich M, Grön G, Prost M, Plener PL, Fegert JM, et al. Fear extinction learning and anandamide: an fMRI study in healthy humans. Transl Psychiatry. 2021;11:161.
112 Habib AM, Okorokov AL, Hill MN, Bras JT, Lee MC, Li S, et al. Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. Br J Anaesth. 2019;123:e249-53.
113 Trezza V, Vanderschuren LJ. Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology (Berl). 2008;197:217-27.
114 Trezza V, Damsteegt R, Manduca A, Petrosonio S, Van Kerkhof LW, Pasterkamp RJ, et al. Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats. J Neurosci. 2012;32:14899-908.
115 Gonczarowska N, Tomaz C, Caixeta FV, Malcher-Lopes R, Barros M, Nishijo H, et al. CB1 receptor antagonism in capuchin monkeys alters social interaction and aversive memory extinction. Psychopharmacology (Berl). 2019;236:3413-9.
116 Manduca A, Serradillo M, Camptonoglo P, Palmyre M, Trabace L, Vanderschuren LJ, et al. Strain- and context-dependent effects of the anandamide hydrolysis inhibitor URB597 on social behavior in rats. Eur Neuropsychopharmacol. 2014;24:1337-48.
117 Matroni J, Seiller A, Giuffrida A. Distinct neuronal activation patterns are associated with PPI-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597. Neuron Sci. 2015;110:49-58.
118 Schneider P, Bindila L, Schmahl C, Bohus M, Meyer-Lindenberg A, Lutz B, et al. Adverse social experiences in adolescent rats result in enduring effects on social competence, pain sensitivity and endocannabinoid signaling. Front Behav Neurosci. 2016;10:203.
119 Schmidt ME, Liebowitz MR, Stein MB, Guninfeld J, Van Hove I, Simmons WK, et al. The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42656279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. Neuropsychopharmacology. 2021;46:1004-10.
120 Mayo LM, Aratani A, Lindé J, Morena M, Haataja R, Hammar V, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol Psychiatry. 2020;87:538-47.
121 Paulus MP, Stein MB, Simmons AN, Risbrough VB, Halter R, Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30:1037-43.
122 Boggs DL, Nguyen JD, Morgenstern D, Taffe MA, Ranganathan M. Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010;159:122-8.
123 McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and δ9-thetrahydrocannabinol negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172:737-53.
124 Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30:1037-43.
125 Fogaça MV, Reis FM, Campos AC, Guimarães FS. Effects of intraperitoneal prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of SHT1A receptors and previous stressful experience. Eur Neuropsychopharmacol. 2014;24:410-9.
126 Campos AC, Guimarães FS, Chariotti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl). 1990;100:558-9.
127 Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM, Guimarães FS. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol. 2009;156:181-8.
128 Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking task. Braz J Psychiatry. 2019;41:9-14.
129 Nazario LR, Antonioli RJ, Ciapetti KM, Hallak JE, Zuardi AW, Crippa JA, et al. Reprint of “cannabinoids protects against repeated restraint stress induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)”. Pharmaco Biochem Behav. 2015;139 Pt B:134-40.
130 Zanelati TV, Biolone C, Moreira FA, Guimarães FS, Joca SR. Antidepressant-like effects of cannabinoids in mice: Possible involvement of 5-HT 1A receptors. Br J Pharmacol. 2010;159:122-8.
131 Casarotto PC, Gomes FV, Resstel LB, Guimarães FS. Cannabidiol inhibitory effect on marble-burying behaviour: Involvement of CB1 receptors. Behav Pharmacol. 2010;21:353-8.
132 Levin R, Peres FF, Almeida V, Calzavara MB, Zuardi AW, Hallak JEC, et al. Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the ShR strain. Front Pharmacol. 2014;5:10.
133 Peres FF, Levin R, Suiama MA, Diana MC, Gouveia DA, Almeida V, et al. Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats. Front Pharmacol. 2016;7:343.
134 Elmes MW, Kaczkoza B, Berger WT, Leung K, Ralph BP, Wang L, et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for δ9-thetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem. 2015;290:8711-21.
135 Wilson AA, Garcia A, Parkes J, Houle S, Tong J, Vasdev N. [11C] AG, et al. Effect of cannabidiol on sepsis. J Psychopharmacol. 2011;25:121-30.
136 Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety

Braz J Psychiatry. 2021;00(00)
induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36:1219-28.

150 Masataka N. Anxiolytic effects of repeated cannabinoid treatment in teenagers with social anxiety disorders. Front Psychol. 2019;10:2466.

151 McMaster University. Cannabidiol for the treatment of anxiety disorders: an 8-week pilot study [Internet]. 2018 [cited 2021 20 Jul]. clinicaltrials.gov/ct2/show/study/NCT03549619.

152 Marcin MS, Nemeroff CB. The neurobiology of social anxiety disorder: the relevance of fear and anxiety. Acta Psychiatr Scand Suppl. 2003;108:51-64.

153 Faravelli C, Lo Sauro C, Godini L, Lelli B, Benni L, Pietrini F, et al. Childhood stressful events, HPA axis and anxiety disorders. World J Psychiatry. 2012;2:13-25.

154 Page ME, Orpeza VC, Sparks SE, Qian Y, Menko AS, Van Bockstaele EJ. Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav. 2007;86:162-8.

155 Page ME, Orpeza VC, Van Bockstaele EJ. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett. 2008;431:1-5.

156 Bambico FR, Katz N, Debonnel G, Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci. 2007;27:11700-11.

157 Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A. 2005;102:18620-5.

158 Cassano T, Gaetani S, Macheda T, Laconca L, Romano A, Morgese MG, et al. Evaluation of the emotional phenotype and serotonin neurotransmission of fatty acid amide hydrolase-deficient mice. Psychoneuroendocrinology (Berl). 2011;24:465-76.

159 Micale V, Drago F. Endocannabinoid system, stress and HPA axis. Eur J Pharmacol. 2018;834:230-9.

160 Gray JM, Wilson CD, Lee TT, Pittman QJ, Deussing JM, Hillard CJ, et al. Sustained glucocorticoid exposure recruits cortico-limbic CRH signaling to modulate endocannabinoid function. Psychoneuroendocrinology. 2016;68:151-8.

161 Hill MN, McLaughlin RJ, Morrish AC, Vivia V, Floresco SB, Hillard CJ, et al. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology. 2009;34:2733-45.

162 Di S, Malcher-Lopes R, Halmos KC, Tasker JG. Nongenomic cannabinoid transmission in the hippocampus activates nucleus accumbens neurons and modulates reward and aversion-related emotional salience. Biol Psychiatry. 2016;80:216-25.

163 Moreira M, Karamar C, Renard J, Rosen LG, Laviolette SR. Cannabinoid transmission in the hippocampus activates nucleus accumbens neurons and modulates reward and aversion-related emotional behavior. Front Neuropathol. 2006;3:304-11.

164 Trezza V, Vanderschuren LJ. Cannabinoid and opioid modulation of social play behavior in adolescent rats: differential behavioral mechanisms. Eur Neuropsychopharmacology. 2008;18:519-30.

165 Schneider M, Schömg E, Leweke FM. Acute and chronic cannabinoids treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol. 2008;13:345-57.

166 Realini N, Viganò D, Guidali C, Zamberletti E, Rubinó T, Parolaro D. Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. Neuropharmacology. 2011;60:235-43.

167 Seillier A, Advani T, Cassano T, Hensler JG, Gjirofrida T. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioral responses in normal and PCP-treated rats. Int J Neuropsycopharmacol. 2010;13:373-86.

168 Seillier A, Martinez AA, Gjirofrida A. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia. Neuropsychopharmacology. 2013;38:1816-24.

169 Melancia F, Schiavi S, Servadio M, Campolongo P, Palotti V, Marley M, et al. Sex-specific autonomic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling. Br J Pharmacol. 2018;175:3699-712.

170 Manduca A, Morena M, Campolongo P, Servadio M, Palmery M, Trabace L, et al. Distinct roles of the endocannabinoids anandamide and 2-arachidonoylglycerol in social behavior and emotionality at different developmental ages in rats. Eur Neuropsychopharmacol. 2015;25:1362-74.

171 Schiavi S, Manduca A, Segatto M, Campolongo P, Pallottini V, Vanderschuren LJ, et al. Unidirectional opioid-cannabinoid cross-tolerance in the modulation of social play behavior in rats. Psychopharmacology (Berl). 2019;236:2557-68.

172 Mordenti J, Eisenstein SA, Astarita G, D’Ascenzi M, Hohmann AG. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology (Berl). 2008;200:333-46.

173 Qin M, Zeidler Z, Moulton K, Krych L, Xia Z, Smith CB. Endocannabinoid-mediated improvement on a test of averse memory in a mouse model of fragile X syndrome. Behav Brain Res. 2015;291:164-71.

174 Seillier A, Gjirofrida A. The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: Further evidence for transporter-mediated endocannabinoid release. Neuropsychopharmacology. 2018;130:1-9.

175 Shahbaz F, Grandi V, Baranee J, Tran T. Cannabinoids and cannabinoid receptors: the story so far. iScience. 2020;23:101301.

176 Doenni VM, Gray JM, Song CM, Patel S, Hill MN, Pittman QJ. Deficient adolescent social behavior following early-life inflammatory stress is ameliorated by augmentation of anandamide signaling. Brain Behav Immun. 2016;58:237-47.

177 Sam AH, Salem V, Ghatei MA. Rimonabant: from RIO to Ban. Br J Obes. 2011;2011:432607.

178 Litvin Y, Phan A, Hill MN, Pfaff DW, McEwen BS. CB1 receptor signaling regulates social anxiety and memory. Genes Brain Behav. 2013;12:479-89.

179 Bogathy E, Kostyalik D, Petschner P, Vas S, Bagdy G. Blockade of serotonin 2C receptors with SB-242084 moderates reduced locomotor activity and rearing by cannabinoid 1 receptor antagonist AM-251. Pharmacology. 2019;103:151-8.

180 Gveye AB, Pryslavsky Y, Trigo JM, Pouila N, Delis F, Antionio K, et al. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimobabant for nicotine dependence and weight loss with better psychiatric tolerability. Int J Neuropsychopharmacol. 2016;19:pyw098.

181 Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, et al. Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol. 2010;20:112-22.

182 O’Brien LD, Wills KL, Segworth B, Dashney B, Rock EM, Limebeer CL, et al. Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacol Biochem Behav. 2013;103:597-602.

183 Jutkiewicz EM, Makriyannis A, Vemuri K, Bergman J. Pro-depressive-like effects of CB1 receptor inverse agonists/antagonists in a mouse model of fragile X syndrome. Behav Brain Res. 2008;197:284-94.

184 Boga A, Kostyalik D, Petschner P, Vas S, Bagdy G. Blockade of serotonin 2C receptors with SB-242084 moderates reduced locomotor activity and rearing by cannabinoid 1 receptor antagonist AM-251. Pharmacology. 2019;103:151-8.

185 Guney AB, Pryslavsky Y, Trigo JM, Pouila N, Delis F, Antionio K, et al. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimobabant for nicotine dependence and weight loss with better psychiatric tolerability. Int J Neuropsychopharmacol. 2016;19:pyw098.

186 Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, et al. Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol. 2010;20:112-22.

187 O’Brien LD, Wills KL, Segworth B, Dashney B, Rock EM, Limebeer CL, et al. Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacol Biochem Behav. 2013;103:597-602.

188 Jutkiewicz EM, Makriyannis A, Vemuri K, Bergman J. Pro-depressive-like effects of CB1 receptor inverse agonists/antagonists in a mouse model of fragile X syndrome. Behav Brain Res. 2008;197:284-94.
The role of CB1 receptors in psychostimulant addiction. Addict Biol. 2008;13:225-38.

Parsons LH, Hurd YL. Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci. 2015;16:579-94.

Mulpuri Y, Marty VN, Munier JJ, Mackie K, Schmidt BL, Seltzman HH, et al. Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. Neuropsychopharmacology. 2018;139:85-97.

Silvicki RA, Xu Z, Kulkarni PG, Mackie K, Thakur GA, et al. Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence. Biol Psychiatry. 2018;84:722-33.

Stasiulewicz A, Znajdek K, Grudzien M, Pawinski T, Sulkowska JI. A guide to targeting the endocannabinoid system in drug design. Int J Mol Sci. 2020;21:2778.

Rubino T, Realini N, Castiglioni C, Guidali C, Vigano D, Marras E, et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex. 2008;18:1292-301.

Befort K. Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Front Pharmacol. 2015;6:6.

Carvalho AF, Van Bockstaele EJ. Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38:59-67.

Buisseret B, Alhouayek M, Guillemot-Legris O, Muccioli GG. Endocannabinoid and prostanoid crosstalk in pain. Trends Mol Med. 2019;25:882-96.

Haj-Dahmane S, Shen Y. Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology. 2011;61:414-20.

Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, et al. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioural analysis. Neuropharmacology. 2008;54:815-23.

Rodriguez-Munoz M, Sanchez-Blazquez P, Merlos M, Garzon-Niño J. Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget. 2016;7:55840.

Musella A, Fresegna D, Rizzo FR, Gentile A, Bullitta S, De Vito F, et al. A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum. Sci Rep. 2017;7:7363.

Michopoulos V, Powers A, Gillespie CF, Ressler KJ, Jovanovic T. Inflammation in fear-and anxiety-based disorders: PTSD, GAD, and beyond. Neuropsychopharmacology. 2017;42:254-70.

Uzun N, Akin MA. Hemogram parameters in childhood anxiety disorders: could anxiety disorders be related with inflammation? Med Hypotheses. 2021;146:110440.